宣泰医药
(688247)
| 流通市值：16.31亿 | | | 总市值：51.95亿 |
| 流通股本：1.42亿 | | | 总股本：4.53亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 297,635,969.73 | 267,008,612.93 | 229,422,987.49 | 641,783,808.7 |
| 应收票据及应收账款 | 107,413,000.95 | 71,260,041.38 | 73,499,119.11 | 65,919,444.72 |
| 应收账款 | 107,413,000.95 | 71,260,041.38 | 73,499,119.11 | 65,919,444.72 |
| 预付款项 | 14,079,955.42 | 22,837,185.37 | 26,581,789.79 | 17,856,445.39 |
| 其他应收款合计 | 4,862,460.19 | 3,174,961.56 | 2,572,324.18 | 2,167,143.94 |
| 存货 | 107,253,297.36 | 80,953,188.46 | 80,949,554.54 | 84,609,475.73 |
| 合同资产 | 11,091,821.57 | 11,491,162.37 | 12,582,706.06 | 12,551,220.3 |
| 其他流动资产 | 8,788,010.09 | 7,400,017.9 | 10,842,778.87 | 127,121,199.56 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,001,124,515.31 | 945,125,169.97 | 945,451,260.04 | 952,008,738.34 |
| 非流动资产: | | | | |
| 长期股权投资 | 63,759,966.36 | 65,190,069.76 | 63,629,205.89 | 64,197,542.19 |
| 固定资产 | 247,962,967.87 | 249,198,018.42 | 253,414,557.5 | 255,965,981.09 |
| 在建工程 | 32,533,880.59 | 22,756,379.79 | 16,733,390.72 | 15,354,678.6 |
| 使用权资产 | 39,724.19 | 54,620.75 | 69,517.31 | 84,413.87 |
| 无形资产 | 22,508,845.51 | 24,163,542.85 | 25,865,499.05 | 27,591,084.7 |
| 商誉 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 |
| 长期待摊费用 | 882,974.62 | 1,026,110.76 | 1,195,755.33 | 1,211,314.47 |
| 递延所得税资产 | 17,622,417.22 | 16,237,253.11 | 15,482,396.53 | 14,285,674.75 |
| 其他非流动资产 | 24,652,498.27 | 19,216,052.34 | 13,061,892.5 | 12,535,073.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 428,349,025.37 | 416,227,798.52 | 407,837,965.57 | 409,611,514.21 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,429,473,540.68 | 1,361,352,968.49 | 1,353,289,225.61 | 1,361,620,252.55 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 21,751,426.17 | 18,342,633.61 | 13,850,247.59 | 14,527,332.94 |
| 应付账款 | 21,751,426.17 | 18,342,633.61 | 13,850,247.59 | 14,527,332.94 |
| 合同负债 | 42,656,632.18 | 35,854,403.74 | 53,319,684.31 | 47,610,636.97 |
| 应付职工薪酬 | 11,038,829.11 | 10,040,669.36 | 8,591,742.24 | 12,755,230.42 |
| 应交税费 | 8,709,191.55 | 2,942,850.97 | 4,546,593.56 | 2,009,999.94 |
| 其他应付款合计 | 26,782,865.79 | 12,760,832.75 | 12,812,985.84 | 11,843,899.22 |
| 应付股利 | 11,228,847.28 | - | - | - |
| 一年内到期的非流动负债 | 22,087.39 | 54,335.38 | 63,257.19 | 62,671.54 |
| 其他流动负债 | 1,411,356.36 | 818,665.13 | 1,955,938.27 | 1,907,559.35 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 112,372,388.55 | 80,814,390.94 | 95,140,449 | 90,717,330.38 |
| 非流动负债: | | | | |
| 租赁负债 | - | - | 6,557.71 | 22,431.78 |
| 递延收益 | 77,622,918.32 | 67,108,823.14 | 54,823,883.23 | 58,087,773.53 |
| 递延所得税负债 | 2,426,870.72 | 2,462,507.63 | 2,498,144.53 | 2,533,781.44 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 80,049,789.04 | 69,571,330.77 | 57,328,585.47 | 60,643,986.75 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 192,422,177.59 | 150,385,721.71 | 152,469,034.47 | 151,361,317.13 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 453,340,000 | 453,340,000 | 453,340,000 | 453,340,000 |
| 资本公积 | 512,869,911.23 | 512,870,241.86 | 512,871,036.84 | 512,890,878.87 |
| 减:库存股 | 36,126,025.26 | 35,005,569.17 | 32,314,700.39 | - |
| 其他综合收益 | -120,689.76 | -134,800.23 | -131,399.76 | -131,292.42 |
| 盈余公积 | 24,565,923.73 | 24,565,923.73 | 24,565,923.73 | 24,565,923.73 |
| 未分配利润 | 282,522,243.15 | 255,331,450.59 | 242,489,330.72 | 219,593,425.24 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,237,051,363.09 | 1,210,967,246.78 | 1,200,820,191.14 | 1,210,258,935.42 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,237,051,363.09 | 1,210,967,246.78 | 1,200,820,191.14 | 1,210,258,935.42 |
| 负债和股东权益合计 | 1,429,473,540.68 | 1,361,352,968.49 | 1,353,289,225.61 | 1,361,620,252.55 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |